Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC — Stella

Recruiting

Back to Esophageal Cancer trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Tianjin Cancer Hospital, Tianjin, Tianjin Municipality

Key details

Phase

Safety & dosing

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Collaborators

Shanxi Province Cancer Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Enrollment target

~52 participants

Started

March 2025

Primary completion

September 2026

Age range

70 Years – 90 Years

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov